Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

BACKGROUND: Excess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter (URAT)1 is important for regulation of serum uric acid (sUA) levels. The URAT1 inhibitors probenecid and benzbromarone a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Arthritis Res Ther
Main Authors: Miner, Jeffrey, Tan, Philip K., Hyndman, David, Liu, Sha, Iverson, Cory, Nanavati, Payal, Hagerty, David T., Manhard, Kimberly, Shen, Zancong, Girardet, Jean-Luc, Yeh, Li-Tain, Terkeltaub, Robert, Quart, Barry
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2016
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5048659/
https://ncbi.nlm.nih.gov/pubmed/27716403
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-016-1107-x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares